KFDA announced in advance revised draft for drug safety and efficacy evaluation guidelines.
According to the new provisions, the health registration of the new drug developed overseas does not require a domestic clinical phase III study from July 1 this year, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
